Media headlines about Alnylam Pharmaceuticals (NASDAQ:ALNY) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 47.4271587616892 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- RNA interference therapies could be on the cusp of success (pharmaceutical-journal.com)
- Why Buy? Reason to know? Alnylam Pharmaceuticals, Inc. (ALNY) (nysestocks.review)
- BRIEF-Alnylam Appoints Colleen Reitan To The Board Of Directors (reuters.com)
- Alnylam Pharmaceuticals, Inc. (ALNY) has analyst mean rating score of 2.20 (nasdaqfortune.com)
- Alnylam Pharma (ALNY) Names Colleen Reitan to Board (streetinsider.com)
Several research firms recently commented on ALNY. BidaskClub raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, March 14th. Credit Suisse Group increased their price objective on Alnylam Pharmaceuticals from $151.00 to $154.00 and gave the company an “outperform” rating in a research report on Tuesday, March 13th. JMP Securities increased their price objective on Alnylam Pharmaceuticals from $169.00 to $207.00 and gave the company an “outperform” rating in a research report on Monday, March 26th. Leerink Swann increased their price objective on Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the company a “market perform” rating in a research report on Thursday, January 25th. Finally, Evercore ISI started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, March 28th. They set a “line” rating and a $143.00 price objective on the stock. Four investment analysts have rated the stock with a sell rating, four have assigned a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $137.05.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.06. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The firm had revenue of $21.90 million for the quarter, compared to the consensus estimate of $35.23 million. During the same quarter last year, the company earned ($1.25) earnings per share. The business’s revenue for the quarter was up 15.3% compared to the same quarter last year. research analysts anticipate that Alnylam Pharmaceuticals will post -6.7 EPS for the current year.
In other news, SVP Laurie Keating sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $145.00, for a total value of $2,900,000.00. Following the transaction, the senior vice president now owns 24,500 shares of the company’s stock, valued at $3,552,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Philip A. Sharp sold 15,000 shares of the firm’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $129.00, for a total value of $1,935,000.00. Following the completion of the transaction, the director now directly owns 155,795 shares in the company, valued at approximately $20,097,555. The disclosure for this sale can be found here. Insiders sold 198,620 shares of company stock worth $28,404,143 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.